Vir Biotechnology, Inc.
VIRNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for VIR. That does not mean none is planned.
Get an email about VIR's next catalysts
Track Vir Biotechnology (VIR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 4 past
Tobevibart Phase 3 Est. Readout
Estimated primary completion for Tobevibart trial (NCT07128550) in Viral Hepatitis. Topline data typically follows completion by weeks to months.
44% of patients who received once-monthly tobevibart and (combination partner truncated in article) achieved the study's response endpoint; first of three late-stage studies to succeed.
SourceMarket Overview
Stock performance and key metrics
Tobevibart
Viral Hepatitis
Elebsiran
Viral Hepatitis
VIR-7831 (sotrovimab)
Covid19
Bulevirtide
Viral Hepatitis
MP0420
Covid19
VIR-2218
Hepatitis B, Chronic
pegylated interferon-alfa 2a
Chronic Hepatitis B
VIR-5818
Locally Advanced or Metastatic HER2-Expressing Cancers
VIR-3434
Hepatitis B, Chronic
BRII-835
Chronic Hepatitis B Virus Infection
BRII-179
For Treatment of Chronic Hepatitis B Virus Infection
PEG-IFNΞ±
Chronic Hepatitis B Virus Infection
Sotrovimab (Gen2)
Covid19
BRII-835 (VIR-2218)
For Treatment of Chronic Hepatitis B Virus Infection
Sotrovimab (Gen1)
Covid19
Selgantolimod
Chronic Hepatitis B
NRTI
Hepatitis D, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tobevibart | Phase 3 | Viral Hepatitis | - | - |
Elebsiran | Phase 3 | Viral Hepatitis | - | - |
VIR-7831 (sotrovimab) | Phase 3 | Covid19 | - | - |
Bulevirtide | Phase 3 | Viral Hepatitis | - | - |
MP0420 | Phase 3 | Covid19 | - | - |
VIR-2218 | Phase 2 | Hepatitis B, Chronic | - | - |
pegylated interferon-alfa 2a | Phase 2 | Chronic Hepatitis B | - | - |
VIR-5818 | Phase 2 | Locally Advanced or Metastatic HER2-Expressing Cancers | - | - |
VIR-3434 | Phase 2 | Hepatitis B, Chronic | - | - |
BRII-835 | Phase 2 | Chronic Hepatitis B Virus Infection | - | - |
BRII-179 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | - | - |
PEG-IFNΞ± | Phase 2 | Chronic Hepatitis B Virus Infection | - | - |
Sotrovimab (Gen2) | Phase 2 | Covid19 | - | - |
BRII-835 (VIR-2218) | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | - | - |
Sotrovimab (Gen1) | Phase 2 | Covid19 | - | - |
Selgantolimod | Phase 2 | Chronic Hepatitis B | - | - |
NRTI | Phase 2 | Hepatitis D, Chronic | - | - |
Viral Hepatitis
3 drugs in this indication
Covid19
2 drugs in this indication
Chronic Hepatitis B
2 drugs in this indication
Hepatitis B, Chronic
2 drugs in this indication
Late-line metastatic castration-resistant prostate cancer (mCRPC)
1 drug in this indication
Hepatitis D, Chronic
1 drug in this indication
Locally Advanced or Metastatic HER2-Expressing Cancers
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Vir Biotechnology, Inc.'s drug pipeline?β
CatalystAlert tracks 17 drug candidates in Vir Biotechnology, Inc.'s (VIR) pipeline across Phase 3, Phase 2. Its lead program is Tobevibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vir Biotechnology, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Vir Biotechnology, Inc. (VIR) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track VIR biotech catalysts?β
Add VIR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vir Biotechnology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
